The U.S. Food and Drug Administration said that it approved Votrient (pazopanib). Votrient is manufactured by GlaxoSmithKline plc (GSK, GSK.L). Votrient is an oral medication that interferes with angiogenesis, the growth of new blood vessels needed for solid tumors to grow and survive.
Votrient is intended for people with advanced renal cell carcinoma, a type of kidney cancer in which the cancerous cells are found in the lining of very small tubes (tubules) in the kidney.
For comments and feedback: editorial@rttnews.com